Company intelligence / Profile preview

Savient Pharmaceuticals

East Brunswick, New Jersey, United Statesen.wikipedia.org ↗

Ownership: Private
Employees: ~82
Development stage: Commercial

Overview

Savient's lead product, pegloticase (Krystexxa), was a biologic drug for treatment-resistant chronic gout, which it marketed beginning in 2011. The company also marketed oxandrolone beginning in 1995, a drug used to promote weight gain following involuntary weight loss[1].

Therapeutic areas: EndocrinologyRheumatology
Modalities: BiologicsSmall molecules
Industry: Biotech

Drug pipeline

2 assets

pegloticase

Approved

1 more asset in the full pipeline.

Request access →

Partnerships

Duke UniversityMountain View Pharmaceuticals, Inc.

Beyond the preview

Go deeper on Savient Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Savient Pharmaceuticals.

Explore the full profile